naxitamab-gqgk

Several weeks after getting hit with an RTF, Y-mAbs lands approval for its other neuroblastoma candidate
Endpoints
Mon, 11/30/20 - 10:36 am
Y-mAbs
neuroblastoma
FDA
naxitamab-gqgk